|
|

Title: Mucoadhesive compositions for
administration of biologically active agents to animal tissue
United States Patent: 5,942,243
Inventors: Shah; Kishore R. (Bridgewater, NJ)
Assignee: Polytherapeutics, Inc. (Brdigewater, NJ)
Appl. No.: 076216
Filed: May 12, 1998
Abstract
This invention pertains to mucoadhesive compositions for the
delivery of pharmacologically active agents, and to polymeric
formulations that allow for a prolonged, sustained release of the
active agents. More specically the invention pertains to
compositions for the delivery of drugs to mucosal tissue, said
composition comprising a drug or a plurality of drugs to be
delivered and a thermoplastic graft copolymer, said graft
copolymer being the reaction product of a polystyrene macromonomer
having an ethylenically unsaturated functional group, and at least
one acidic hydrophilic monomer having an ethylenically unsaturated
functional group.
Summary of the Invention
The present invention pertains to polymeric mucoadhesive
compositions consisting essentially of a graft copolymer
comprising a hydrophilic main chain and hydrophobic graft chains
for controlled release of biologically active agents. The graft
copolymer is a reaction product of
(1) a polystyrene macromonomer having an ethylenically unsaturated
functional group, and
(2) at least one hydrophilic acidic monomer having an
ethylenically unsaturated functional group.
The graft chains consist essentially of polystyrene, and the main
polymer chain of hydrophilic monomeric moieties, some of which
have acidic functionality. The weight percent of the polystyrene
macromonomer in the graft copolymer is between about 1 and about
20% and the weight percent of the total hydrophilic monomer in the
graft copolymer is between 80 and 99%, and wherein at least 10% of
said total hydrophilic monomer is acidic, said graft copolymer
when fully hydrated having an equilibrium water content of at
least 90%.
Compositions containing the copolymers gradually hydrate by
sorption of tissue fluids at the application site to yielding a
very soft jelly like mass exhibiting adhesion to the mucosal
surface. During the period of time the composition is adhered to
the mucosal surface it provides sustained release of the
pharmacologically active agent, which is absorbed by the mucosal
tissue.
Mucoadhesivity of the compositions of this invention is, to a
large extent, produced by the hydrophilic acidic monomers of the
chain in the polystyrene graft copolymer. The acidic monomers
include, but are not limited to, acrylic and methacrylic acids,
2-acrylamido-2-methyl-propane sulfonic acid, 2-sulfoethyl
methacrylate, and vinyl phosphonic acid. Other copolymerizable
monomers include, but are not limited to N,N-dimethylacrylamide,
glyceryl methacrylate, polyethylene glycol monomethacrylate, etc.
The compositions of the present invention may optionally contain
other polymeric materials, such as poly(acrylic acid),
poly,-(vinyl pyrrolidone), and sodium carboxymethyl cellulose
plasticizers, and other pharmaceutically acceptable excipients in
amounts that do not cause deleterious effect upon mucoadhesivity
of the composition. The dosage forms of the compositions of this
invention can be prepared by conventional methods.
The various pharmaceutically active agents that may be used
include drugs for systemic treatment of conditions as well as
local treatment of conditions. Various treatments include drugs
for neurological conditions, cardiovascular conditions,
inflammatory diseases, pain relief, anticancer drugs, microbial
infections, prevention of conception and the like. Peptide and
protein drugs are specialty suitable for delivery via the mucosal
route, because they are readily destroyed through the
gastrointestinal tract when administered orally.
It is an object of the present invention to provide a controlled
release polymeric composition for one or more biologically or
pharmacologically active agents. Another object of the present
invention is to provide a pharmaceutical dosage form which is
water swellable but water insoluble. The dosage form can easily be
formulated as user friendly articles such as powders, capsules,
suppositories, ointments, films, laminates, tablets, solutions,
dispersions and the like. In addition, the dosage form may be in a
dehydrated state, or plasticized with a suitable plasticizer, or
in a partially hydrated state.
A further object of this invention is to provide a pharmaceutical
dosage form which exhibits adhesion to the mucous surfaces of
animal tissues, but no local side effects or toxicity. Various
mucosal sites in the body, to which the compositions of this
invention may be applied, include cul-de-sac of the eye, oral
mucosa, nose, rectum, vagina, periodontal pocket, intestines and
colon.
Another object of the present invention is to provide a
composition which is at once both convenient to formulate with a
biologically, active agent and economical to manufacture.
The invention also envisions a method of treatment by application
of the controlled release composition to a mucosal tissue. The
application of the composition to the mucosa of the
gastrointestinal tract may be carried out by swallowing the
composition.
Claim 1 of 21 Claims
1. A mucoadhesive hydrophilic drug delivery system comprising:
(A) a drug or a plurality of drugs to be delivered, and
(B) a drug delivery vehicle consisting essentially of a
thermoplastic graft copolymer, said graft copolymer being a
reaction product of:
(1) a polystyrene macromonomer having an ethylenically unsaturated
functional group, and
(2) at least one hydrophilic acidic monomer having an
ethylenically unsaturated functional group,
wherein the weight percent of the polystyrene macromonomer in the
graft copolymer is between about 1 and about 20%, and the weight
percent of the total hydrophilic monomer in the graft copolymer is
between 80 and 99%, wherein at least about 10% of said total
hydrophilic monomer is acidic, said graft copolymer when fully
hydrated having an equilibrium water content of at least 90%,
said graft copolymer being present in said drug delivery system in
an amount sufficient to cause said drug delivery system to form a
water swollen but insoluble jelly like mass upon contact with the
biological environment.
____________________________________________
If you want to learn more
about this patent, please go directly to the US
Patent and Trademark Office web site to access the full
patent.
|